Literature DB >> 15519522

A gene-environment interaction between occupation and BRCA1/BRCA2 mutations in male breast cancer?

Domenico Palli1, Giovanna Masala, Renato Mariani-Costantini, Ines Zanna, Calogero Saieva, Francesco Sera, Adriano Decarli, Laura Ottini.   

Abstract

The association of male breast cancer (MBC) with a positive breast cancer (BC) family history and with BRCA1/2 germ-line mutations points to a genetic component; a relationship with occupation has also been reported. Recently, we identified pathogenetic BRCA1/2 mutations in a population-based series of Italian MBC patients: here in, we investigated interactions between a carrier status for BRCA1/2 mutations and occupation using a case-case design and estimating case-only odds ratios (CORs). Truck-driving was the most frequent occupation (3/4 BRCA-related cases and 2/19 unrelated cases). An interaction between carrier status and working as a truck-driver emerged, when we classified MBC cases as "ever/never-held" this job title (COR 25.5; 95% Confidence Limits (CL): 1.1-1,412.5) or according to truck-driving as the "longest-held" work (COR 54.0; 95% CL: 1.6-2,997.5). The possible modifying effect on MBC risk in subjects carrying BRCA1/2 germ-line mutations of an occupation characterised by exposure to chemicals such as polycyclic aromatic hydrocarbons (PAH) that are capable of inducing DNA damage, may provide clues to the role of environmental exposures in modifying BC risk in mutation carriers in both genders.

Entities:  

Mesh:

Year:  2004        PMID: 15519522     DOI: 10.1016/j.ejca.2004.07.012

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

Review 1.  State of the evidence 2017: an update on the connection between breast cancer and the environment.

Authors:  Janet M Gray; Sharima Rasanayagam; Connie Engel; Jeanne Rizzo
Journal:  Environ Health       Date:  2017-09-02       Impact factor: 5.984

Review 2.  Male Breast Cancer.

Authors:  Metin Yalaza; Aydın İnan; Mikdat Bozer
Journal:  J Breast Health       Date:  2016-01-01

3.  Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

Authors:  Valentina Silvestri; Goska Leslie; Daniel R Barnes; Bjarni A Agnarsson; Kristiina Aittomäki; Elisa Alducci; Irene L Andrulis; Rosa B Barkardottir; Alicia Barroso; Daniel Barrowdale; Javier Benitez; Bernardo Bonanni; Ake Borg; Saundra S Buys; Trinidad Caldés; Maria A Caligo; Carlo Capalbo; Ian Campbell; Wendy K Chung; Kathleen B M Claes; Sarah V Colonna; Laura Cortesi; Fergus J Couch; Miguel de la Hoya; Orland Diez; Yuan Chun Ding; Susan Domchek; Douglas F Easton; Bent Ejlertsen; Christoph Engel; D Gareth Evans; Lidia Feliubadalò; Lenka Foretova; Florentia Fostira; Lajos Géczi; Anne-Marie Gerdes; Gord Glendon; Andrew K Godwin; David E Goldgar; Eric Hahnen; Frans B L Hogervorst; John L Hopper; Peter J Hulick; Claudine Isaacs; Angel Izquierdo; Paul A James; Ramunas Janavicius; Uffe Birk Jensen; Esther M John; Vijai Joseph; Irene Konstantopoulou; Allison W Kurian; Ava Kwong; Elisabetta Landucci; Fabienne Lesueur; Jennifer T Loud; Eva Machackova; Phuong L Mai; Keivan Majidzadeh-A; Siranoush Manoukian; Marco Montagna; Lidia Moserle; Anna Marie Mulligan; Katherine L Nathanson; Heli Nevanlinna; Joanne Ngeow; Liene Nikitina-Zake; Kenneth Offit; Edith Olah; Olufunmilayo I Olopade; Ana Osorio; Laura Papi; Sue K Park; Inge Sokilde Pedersen; Pedro Perez-Segura; Annabeth H Petersen; Pedro Pinto; Berardino Porfirio; Miquel Angel Pujana; Paolo Radice; Johanna Rantala; Muhammad U Rashid; Barak Rosenzweig; Maria Rossing; Marta Santamariña; Rita K Schmutzler; Leigha Senter; Jacques Simard; Christian F Singer; Angela R Solano; Melissa C Southey; Linda Steele; Zoe Steinsnyder; Dominique Stoppa-Lyonnet; Yen Yen Tan; Manuel R Teixeira; Soo H Teo; Mary Beth Terry; Mads Thomassen; Amanda E Toland; Sara Torres-Esquius; Nadine Tung; Christi J van Asperen; Ana Vega; Alessandra Viel; Jeroen Vierstraete; Barbara Wappenschmidt; Jeffrey N Weitzel; Greet Wieme; Sook-Yee Yoon; Kristin K Zorn; Lesley McGuffog; Michael T Parsons; Ute Hamann; Mark H Greene; Judy A Kirk; Susan L Neuhausen; Timothy R Rebbeck; Marc Tischkowitz; Georgia Chenevix-Trench; Antonis C Antoniou; Eitan Friedman; Laura Ottini
Journal:  JAMA Oncol       Date:  2020-08-01       Impact factor: 31.777

Review 4.  HER2-positive male breast cancer: an update.

Authors:  Laura Ottini; Carlo Capalbo; Piera Rizzolo; Valentina Silvestri; Giuseppe Bronte; Sergio Rizzo; Antonio Russo
Journal:  Breast Cancer (Dove Med Press)       Date:  2010-10-04

5.  Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy.

Authors:  Domenico Palli; Mario Falchetti; Giovanna Masala; Ramona Lupi; Francesco Sera; Calogero Saieva; Cristina D'Amico; Marco Ceroti; Piera Rizzolo; Maria Adelaide Caligo; Ines Zanna; Laura Ottini
Journal:  BMC Cancer       Date:  2007-09-03       Impact factor: 4.430

6.  SULT1A1 gene deletion in BRCA2-associated male breast cancer: a link between genes and environmental exposures?

Authors:  Domenico Palli; Piera Rizzolo; Ines Zanna; Valentina Silvestri; Calogero Saieva; Mario Falchetti; Anna Sara Navazio; Veronica Graziano; Giovanna Masala; Simonetta Bianchi; Antonio Russo; Stefania Tommasi; Laura Ottini
Journal:  J Cell Mol Med       Date:  2013-05       Impact factor: 5.310

7.  Male breast cancer, clinical presentation, diagnosis and treatment: Twenty years of experience in our Breast Unit.

Authors:  A Sanguinetti; A Polistena; R Lucchini; M Monacelli; S Galasse; S Avenia; R Triola; W Bugiantella; R Cirocchi; F Rondelli; N Avenia
Journal:  Int J Surg Case Rep       Date:  2016-02-26

8.  A Functional Polymorphism (rs10817938) in the XPA Promoter Region Is Associated with Poor Prognosis of Oral Squamous Cell Carcinoma in a Chinese Han Population.

Authors:  Chunhai Gao; Jinzhu Wang; Chong Li; Wei Zhang; Guoxia Liu
Journal:  PLoS One       Date:  2016-09-13       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.